Eli Lilly is making its biggest bet on psychedelic medicine, announcing a 2.8 billion dollar acquisition of AtaiBeckley that marks a watershed moment for the once-fringe field of psychedelic therapy. The deal, announced Thursday, gives the pharmaceutical giant access to experimental treatments based on DMT and MDMA that could transform how treatment-resistant depression is addressed.

AtaiBeckley's lead drug, BPL-003, is a nasal spray derived from dimethyltryptamine—better known as DMT—that is currently in Phase 3 clinical trials for treatment-resistant depression. The drug is administered in a clinic setting where patients are monitored for about two hours, with initial results from the pivotal trials expected in 2029.

A Different Approach to Depression

Eli Lilly's chief scientific officer, Dan Skovronsky, explained the company's rationale in an interview with CNBC: "The goal here was to find a different type of medicine that could help them, not just changing the neurotransmitters in their brain, but actually changing the connections of neurons in their brain to try and help them from the disease."

Unlike traditional antidepressants such as Prozac—which Lilly once dominated the market with—psychedelics may work by rapidly prompting neurons to create new connections. Emerging research suggests people with treatment-resistant depression may lack sufficient plasticity in the brain, and these experimental drugs aim to address that underlying issue.

Skovronsky noted that AtaiBeckley's team found the drug could have a "profound effect very quickly that could persist for months," making it a fundamentally different treatment paradigm. Patients might receive the treatment just a couple of times per year rather than taking daily medication.

Deal Terms and Potential Upside

Lilly will pay 6.75 dollars per share in cash for AtaiBeckley, a 26% premium over the company's Wednesday closing price of 5.36 dollars. The pharma giant could pay an additional 2.50 dollars per share—up to 1 billion dollars total—if AtaiBeckley's drugs meet certain development and regulatory milestones.

The acquisition continues Lilly's aggressive dealmaking pace in 2026. Before announcing the AtaiBeckley purchase, the company had already committed to spending more than 10 billion dollars upfront on eight other acquisitions this year, with potential payments reaching 25 billion dollars including milestone payments.

Psychedelics Gain Mainstream Momentum

The deal reflects growing momentum behind psychedelic-based treatments. The Trump administration has prioritized development of psychedelic therapies for mental health conditions including depression and post-traumatic stress disorder, lending federal support to what was once a controversial field.

Lilly has a long history in mental health treatment. The company's blockbuster antidepressant Prozac transformed depression treatment in the late 1980s and 1990s, fueling Lilly's last major sales boom before its current GLP-1 weight loss drug explosion.

Skovronsky drew parallels between the early resistance to treating depression and current skepticism about psychedelics. "When Lilly started working in the area, there was stigma around treating depression at all," he said. "I compared that to some of the resistance to psychedelics now and said that actually attracts him to the space."

Science Behind the Approach

The scientific understanding of how psychedelics work has advanced significantly. "We understand now the different receptors in the brain that drugs like this bind to, and we understand that those receptors have a signaling cascade inside of neurons that then tells them to become more plastic," Skovronsky explained.

Whether the therapeutic benefit is connected to the hallucinogenic experience remains debated in the field. "For now, we have a medicine that causes both, and as a result, I think has this really important treatment effect," he said.

Implications for Mental Health Treatment

If BPL-003 succeeds in Phase 3 trials, it could offer hope to the estimated 30% of depression patients who don't respond adequately to existing treatments. Treatment-resistant depression affects millions of Americans and represents an enormous unmet medical need.

Lilly's entry into psychedelic medicine with a 2.8 billion dollar commitment signals that major pharmaceutical companies now view this approach as scientifically credible and commercially viable. For patients who have exhausted other options, the deal moves promising new treatments one step closer to reaching the market.